LRRK2 in Parkinson's disease: protein domains and functional insights

Trends in Neurosciences

Volumn 29, Issue 5, 2006, Pages 286-293

  Mata, Ignacio F ^a   Wedemeyer, William J ^b,c   Farrer, Matthew J ^a   Taylor, Julie P ^a   Gallo, Kathleen A ^b,c  

^a MAYO CLINIC   (United States)

^b Michigan State University   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PROTEIN KINASE; UNCLASSIFIED DRUG;

GENE MUTATION; HUMAN; IDIOPATHIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; REGULATOR GENE; REVIEW;

HUMANS; MUTATION; PARKINSON DISEASE; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES;

EID: 33646151866     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2006.03.006     Document Type: Review

References (79)

1. de Rijk, M.C. et al. (2000) Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (11, Suppl. 5), S21-S23
2. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 991 (2003) 1-14
3. Cookson M.R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74 (2005) 29-52
4. Moore D.J., et al. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
5. Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
6. Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
7. Aasly J.O., et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann. Neurol. 57 (2005) 762-765
8. Berg D., et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128 (2005) 3000-3011
9. Khan N.L., et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128 (2005) 2786-2796
10. Mata I.F., et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6 (2005) 171-177
11. Farrer M., et al. LRRK2 mutations in Parkinson disease. Neurology 65 (2005) 738-740
12. Zabetian C.P., et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65 (2005) 741-744
13. Lesage S., et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354 (2006) 422-423
14. Lesage S., et al. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G mutation dating from the 13th century. Am. J. Hum. Genet. 77 (2005) 330-332
15. Ozelius L.J., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354 (2006) 424-425
16. Di Fonzo A., et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365 (2005) 412-415
17. Kachergus J., et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76 (2005) 672-680
18. Nichols W.C., et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365 (2005) 410-412
19. Gilks W.P., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (2005) 415-416
20. Ross O.A., et al. Lrrk2 and Lewy body disease. Ann. Neurol. 59 (2006) 388-393
21. Wszolek Z., et al. German-Canadian family (Family A) with parkinsonism, amyotrophy, and dementia - longitudinal observations. Parkinsonism Relat. Disord. 3 (1997) 125-139
22. Taylor J.P., et al. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. Trends Mol. Med. 12 (2006) 76-82
23. Melrose H., et al. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience (2006). http://www.sciencedirect.com/science/journal/03064522 10.1016/j.neuroscience.2006.01.017 (http://www.sciencedirect.com/science/journal/03064522)
24. Simon-Sanchez J., et al. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci. 23 (2006) 659-666
25. Korr D., et al. LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell. Signal. 18 (2006) 910-920
26. Bosgraaf L., and Van Haastert P.J. Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 1643 (2003) 5-10
27. Manning G., et al. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
28. Andrade M.A., et al. Protein repeats: structures, functions, and evolution. J. Struct. Biol. 134 (2001) 117-131
29. Canagarajah B.J., et al. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90 (1997) 859-869
30. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
31. Nolen B., et al. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 15 (2004) 661-675
32. Toft M., et al. LRRK2 mutations and Parkinsonism. Lancet 365 (2005) 1229-1230
33. Albrecht M. LRRK2 mutations and Parkinsonism. Lancet 365 (2005) 1230
34. Lu C.S., et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat. Disord. 11 (2005) 521-522
35. West A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16842-16847
36. Gloeckner C.J., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15 (2006) 223-232
37. Meylan E., and Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci. 30 (2005) 151-159
38. Johnson G.L., et al. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Curr. Opin. Chem. Biol. 9 (2005) 325-331
39. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002) 1911-1912
40. Ting A.T., et al. RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J. 15 (1996) 6189-6196
41. Wellbrock C., et al. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5 (2004) 875-885
42. Gallo K.A., and Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3 (2002) 663-672
43. Wang L.H., et al. Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 451-474
44. Dhillon A.S., and Kolch W. Untying the regulation of the Raf-1 kinase. Arch. Biochem. Biophys. 404 (2002) 3-9
45. Li W., et al. Function of the Rho family GTPases in Ras-stimulated Raf activation. J. Biol. Chem. 276 (2001) 34728-34737
46. Du Y., et al. Cdc42 induces activation loop phosphorylation and membrane targeting of mixed lineage kinase 3. J. Biol. Chem. 280 (2005) 42984-42993
47. Leung I.W., and Lassam N. Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3. J. Biol. Chem. 273 (1998) 32408-32415
48. Vacratsis P.O., and Gallo K.A. Zipper-mediated oligomerization of the mixed lineage kinase SPRK/MLK-3 is not required for its activation by the GTPase cdc42 but is necessary for its activation of the JNK pathway. J. Biol. Chem. 275 (2000) 27893-27900
49. Stenmark, H. and Olkkonen, V.M. (2001) The Rab GTPase family. Genome Biol. 2reviews3007.1-reviews3007.7
50. Shields J.M., et al. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10 (2000) 147-154
51. Jaffe A.B., and Hall A. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 21 (2005) 247-269
52. Schwartz M. Rho signalling at a glance. J. Cell Sci. 117 (2004) 5457-5458
53. Smith W.W., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18676-18681
54. Ardley H.C., and Robinson P.A. E3 ubiquitin ligases. Essays Biochem. 41 (2005) 15-30
55. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
56. Tanaka K., et al. Ubiquitin, proteasome and parkin. Biochim. Biophys. Acta 1695 (2004) 235-247
57. Marcotte E.M., et al. Detecting protein function and protein-protein interactions from genome sequences. Science 285 (1999) 751-753
58. Mosavi L.K., et al. The ankyrin repeat as molecular architecture for protein recognition. Protein Sci. 13 (2004) 1435-1448
59. Ruas M., et al. Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information. Oncogene 18 (1999) 5423-5434
60. Russo A.A., et al. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395 (1998) 237-243
61. Joutel A., et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383 (1996) 707-710
62. Zweifel M.E., et al. Structure and stability of the ankyrin domain of the Drosophila Notch receptor. Protein Sci. 12 (2003) 2622-2632
63. Kobe B., and Kajava A.V. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol. 11 (2001) 725-732
64. Skipper L., et al. Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology 65 (2005) 1319-1321
65. Yu L., et al. Thirty-plus functional families from a single motif. Protein Sci. 9 (2000) 2470-2476
66. Nash P., et al. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414 (2001) 514-521
67. Yaffe M.B., and Smerdon S.J. The use of in vitro peptide-library screens in the analysis of phosphoserine/threonine-binding domain structure and function. Annu. Rev. Biophys. Biomol. Struct. 33 (2004) 225-244
68. Chen S., et al. Interaction of Gβγ with RACK1 and other WD40 repeat proteins. J. Mol. Cell. Cardiol. 37 (2004) 399-406
69. Ahmadian M.R., et al. Structural fingerprints of the Ras-GTPase activating proteins neurofibromin and p120GAP. J. Mol. Biol. 329 (2003) 699-710
70. Cherfils J., and Chardin P. GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem. Sci. 24 (1999) 306-311
71. Paisan-Ruiz C., et al. LRRK2 gene in Parkinson disease. Neurology 65 (2005) 696-700
72. Mata I.F., et al. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci. Lett. 382 (2005) 309-311
73. Kay D.M., et al. Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics. Mov Disord. (2005)
74. Funayama M., et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 57 (2005) 918-921
75. Kay D.M., et al. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov. Disord. 20 (2005) 1077-1078
76. Ginalski K., et al. 3D-Jury: a simple approach to improve protein structure predictions. Bioinformatics 19 (2003) 1015-1018
77. Altschul S.F., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (1997) 3389-3402
78. Jaroszewski L., et al. FFAS03: a server for profile-profile sequence alignments. Nucleic Acids Res. 33 (2005) W284-W288
79. Koradi R., et al. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14 (1996) 51-55